Código QR (código de barras bidimensional)

Brexpiprazole: A new option in treating agitation in Alzheimer's dementia—Insights from transgenic mouse models

Abstract Aim Brexpiprazole is the first FDA‐approved treatment for agitation associated with dementia due to Alzheimer's disease. Agitation in Alzheimer's dementia (AAD) occurs in high prevalence and is a great burden for patients and caregivers. Efficacy, safety, and tolerability of brexpiprazole w...

Fuld beskrivelse

Na minha lista:
Principais autores: Naoki Amada, Shinji Sato, Dai Ishikawa, Mai Nakamura, Mikio Suzuki, Takashi Futamura, Kenji Maeda
Format: Artigo
Sprog:Inglês
Udgivet: Wiley 2024-09-01
Serier:Neuropsychopharmacology Reports
Fag:
aggression
agitation
Alzheimer's disease
behavioral and psychological symptoms associated with dementia (BPSD)
brexpiprazole
Online adgang:https://doi.org/10.1002/npr2.12461
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker